Nilotinib Hydrochloride

TASIGNA®

Antineoplastic landscape

About TASIGNA®

  1. Marketed by Novartis Pharmaceuticals Corporation
  2. Orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor
  3. Treatment of adult and pediatric patients with newly diagnosed or treatment-resistant Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML)

Approvals

  1. First E.U. approval: November 19, 2007
  2. First U.S. approval: October 29, 2007

Constraint date forecast

  1. Patent expiry: 2023 (United States)
  2. Patent expiry: 2023 (European Union)
  3. Patent expiry: 2028 (Japan)

The future of the generics landscape

Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team